No profile data available.
Lite Strategy, Inc. (LITS) is a healthcare company in the blood cancer treatment drugs industry, based in San Diego, United States, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$15.95 million. In Q4 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $38.62 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2025; market data as of October 9, 2026.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025.
Lite Strategy reported $0 in revenue for fiscal year 2025, down 100.0% from $65.30 million in fiscal year 2024. In Q4 2026 revenue was $0.
$38.62 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Atara Biotherapeutics, Inc. (ATRA), Citius Oncology, Inc. (CTOR), Apollomics, Inc. (APLM), Actinium Pharmaceuticals, Inc. (ATNM).